guest ::
| Home > Publications database > European Association of Neuro-Oncology’s 30th anniversary: A successful and growing relationship with Neuro-Oncology Practice |
| Home > Publications database > European Association of Neuro-Oncology’s 30th anniversary: A successful and growing relationship with Neuro-Oncology Practice |
| Journal Article | FZJ-2025-00578 |
; ; ; ;
2024
Oxford Univ. Press
Oxford
This record in other databases: 
Please use a persistent id in citations: doi:10.1093/nop/npae061
Abstract: ExtractThis month, October 2024, we proudly celebrate the 30th Anniversary of the European Association of Neuro-Oncology (EANO). During our yearly conference, this time in Glasgow, we will look back with many EANO members and colleagues from all over the world to what has been accomplished globally in this unique and challenging oncological subspecialty over the past decades. Diagnosis, treatment, and care for neuro-oncological patients and their families have steadily developed and improved substantially. Thorough (pre)clinical and translational research form the basis for these achievements and guide the training and education for all of us. The achievements are primarily of benefit for our patients and their families, but also for the readership of Neuro-Oncology Practice: practicing healthcare professionals.Neuro-Oncology Practice started as an offspring journal of Neuro-Oncology in 2014 and is dedicated to publishing articles with high relevance for clinical practice, specifically addressing all topics of interest for practicing healthcare professionals. For this goal, the Journal benefits from (invited and unsolicited) reviews, editorials, guidelines, clinical debate, and publication of original research.1–5 To become relevant, both clinical trial data and real-world data need to be interpreted for our readers.6 The same holds true for the key molecular genetics of brain tumors, integrated with histopathology.7 The Response Assessment in Neuro-Oncology (RANO) initiative is another major breakthrough in the field, and it is no longer confined to imaging.8 Clinical outcomes related to functioning and well-being are of equal importance compared to survival and imaging to determine the net clinical benefit of (new) treatments for brain tumor patients.9 With successful treatments, critical issues related to long-term survivorship come along. Tumor-targeted and patient-tailored treatments have eventually become a reality, and caregivers equally deserve our attention and care.10 An upcoming supplement to our journal on the treatment of IDH mutant gliomas will accompany the introduction of IDH inhibitors, which has proved to be the most recent breakthrough.11
; Clarivate Analytics Master Journal List ; Ebsco Academic Search ; Emerging Sources Citation Index ; IF < 5 ; JCR ; SCOPUS ; Web of Science Core Collection
|
The record appears in these collections: |
PDF